Item 8.01. Other Events.



On January 18, 2023, BeiGene, Ltd. ("BeiGene") announced that the National
Reimbursement Drug List ("NRDL") released by China's National Healthcare
Security Administration has been updated to include four new indications for its
PD-1 inhibitor tislelizumab. KYPROLIS®, a proteosome inhibitor licensed-in from
Amgen, is included for the first time and XGEVA®, a RANKL inhibitor and another
Amgen asset, successfully renewed this year. The updated NRDL will officially
take effect on March 1, 2023. The full text of this press release is filed as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.

On January 19, 2023, BeiGene announced that the U.S. Food and Drug
Administration has approved its Bruton's tyrosine kinase inhibitor BRUKINSA
(zanubrutinib) for the treatment of adult patients with chronic lymphocytic
leukemia or small lymphocytic lymphoma. The full text of this press release is
filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated
herein by reference.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.

   Exhibit No.

       99.1              Press release titled "BeiGene Announces Expansion of Coverage on China's
                         National Reimbursement Drug List" issued by

BeiGene, Ltd. on January 18, 2023


       99.2              Press release titled "BRUKINSA® Approved in the

U.S. for Chronic Lymphocytic


                         Leukemia" issued by BeiGene, Ltd. on January 19,

2023


       104               The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses